How T3D-959 works
According to some researchers, Alzheimer’s disease is a metabolic disease caused by age-related metabolic dysfunctions.
It is hoped that by acting on the PPAR proteins, T3D-959 may correct these metabolic dysfunctions and improve the symptoms of the disease.
T3D-959 in clinical trials
A clinical study evaluated the effectiveness and mechanisms of action of T3D-959 in a rat model of Alzheimer’s disease. The results published in the Journal of Alzheimer’s Disease revealed that T3D-959 improved the animal’s spatial learning and memory.
Based on these promising results, a Phase 1/2 feasibility study (NCT02560753) of T3D-959 in people with mild-to-moderate Alzheimer’s disease was initiated and is currently ongoing. Participants are randomly assigned to varying doses of T3D-959 administered by mouth once a day. The primary endpoint is the changes in cerebral metabolic rate for glucose in the regions of the brain preferentially affected by Alzheimer’s disease.
Preliminary results were revealed by the company in a presentation at the 2016 Alzheimer’s Association International Conference. They showed that T3D-959 led to rapid improvement in cognitive tests in more than half (53 percent) of all the participants (a total 36) with mild-to-moderate Alzheimer’s disease.
Alzheimers News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.